EUVIMEDEUVIMED entdecken
Crossref

Bivalent OX40 Aptamer and CpG as Dual Agonists for Cancer Immunotherapy

Tingting Jiang iD, Zailin Yang, Qiuyu Su, Liang Fang iD, Qing Xiang, Cheng Tian, Qinlin Gao, Chengde Mao iD, Cheng Zhi Huang iD, Hua Zuo iD

ACS Applied Materials & Interfaces · 2025

DOI: 10.1021/acsami.4c18550 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2025. Verfasst von Tingting Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Receptors, OX40, Immunotherapy, Oligodeoxyribonucleotides. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing Municipality, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aptamers, NucleotideReceptors, OX40ImmunotherapyOligodeoxyribonucleotidesAnimalsMiceHumansCell Line, TumorMice, Inbred C57BLToll-Like Receptor 9Female

Stichwörter der Autor:innen

CpGDual agonistsImmune therapyNucleic acid aptamerOX40

Substanzen

Aptamers, NucleotideReceptors, OX40OligodeoxyribonucleotidesToll-Like Receptor 9

Autor:innen und Institutionen

  • College of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China.
  • Department of Hematology-Oncology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing 400030, China.
  • Department of Oncology, The Ninth People's Hospital of Chongqing, Chongqing 400700, China.
  • Department of Chemistry, Purdue University, West Lafayette 47907, Indiana, United States.

ORCID-Profile: Tingting Jiang, Liang Fang, Chengde Mao, Cheng Zhi Huang, Hua Zuo

Förderung

  • Natural Science Foundation of Chongqing Municipality
  • National Natural Science Foundation of China

Zitieren

APA

Jiang, T., Yang, Z., Su, Q., Fang, L., Xiang, Q., Tian, C., Gao, Q., Mao, C., Huang, C. Z., & Zuo, H. (2025). Bivalent OX40 Aptamer and CpG as Dual Agonists for Cancer Immunotherapy. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c18550

Vancouver

Jiang T, Yang Z, Su Q, Fang L, Xiang Q, Tian C, et al. Bivalent OX40 Aptamer and CpG as Dual Agonists for Cancer Immunotherapy. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.4c18550

BibTeX
@article{Jiang2025,
  author = {Jiang, Tingting and Yang, Zailin and Su, Qiuyu and Fang, Liang and Xiang, Qing and Tian, Cheng and Gao, Qinlin and Mao, Chengde and Huang, Cheng Zhi and Zuo, Hua},
  title = {Bivalent OX40 Aptamer and CpG as Dual Agonists for Cancer Immunotherapy},
  journal = {ACS Applied Materials & Interfaces},
  year = {2025},
  doi = {10.1021/acsami.4c18550}
}
Kostenlos starten →